2023-09-01 15:53:02
Real time Euronext Paris – 17:36:09 01/09/2023 Varia. 5d. Varies. Jan. 1 3,265 EUR -16.28% +16.82% -53.95% AB Science (-16.28% to 3.27 euros)
Up more than 33% the day before, AB Science tumbled at the close losing more than 16%. Its title has nevertheless gained 16% for a week.
© AOF – 2023
Values quoted in the article
AB Science: biggest drop in the SRD market at the close of Friday, September 1, 2023 – 5:53 p.m. AO AB Science: biggest drop in the SRD market at the mid-session of Friday, September 1, 2023 – 12:19 AO AB Science: more strong rise in the SRD market at the close of Thursday August 31, 2023 – 08/31 AO TME Pharma: positive results in brain tumors 06/28 CF AB Science obtains a European patent for a drug against prostate cancer 06/27 MT AB Science: receives a notice of acceptance for a patent 06/26 CF AB Science SA receives a notice of admissibility for a European patent covering masitinib in the treatment of metastatic castration-resistant prostate cancer (mCRPC) 26/ 06 CI The French AB Science obtains a Canadian patent for a drug against a rare neurological disease. 02/06 MT Alignment of planets in progress 02/06 Stocks to follow today on the Paris Stock Exchange – Friday, June 2, 2023 02/06 AO AB Science: Canadian patent for masitinib in the treatment of ALS 02/06 AO Direct from the Markets: Alstom, Renault, Casino, Broadcom, Lululemon, Dechra, Atos… 02/06 AB Science: Canada grants a patent in the SLA 01/06 CF AB Science: steepest fall in the SRD market at the close of Wednesday May 10, 2023 05/10 AO Direct from the Markets: Crédit Agricole, Alstom, Airbus, Casino, Airbnb, Software AG, Ahold, Alcon… 05/10 AB Science’s revised application for a drug against a rare neurological disease is accepted for review in Canada 05/10 MT AB Science: Health Canada took over the masitinib case 05/09 CF AB Science: biggest decline in the SRD market at the close of Tuesday May 9, 2023 – 05/09 AO First Republic bites the dust in turn 02/05 Direct from the Markets: TotalEnergies, Airbus, McPhy, Logitech, Astellas, Chegg, HSBC, Adidas… 02/05 AB Science: operating loss widened by 15% in 2022 02 /05 CF AB Science SA publishes its results for the year ended December 31, 2022 04/28 CI AB Science SA publishes its results for the year ended December 31, 2022 04/28 CI AB Science SA summarizes the presentation on masitinib in amyotrophic lateral sclerosis at the 2023 American Academy of Neurology Annual Meeting in Boston, USA. 04/27 CI AB Science: To be continued today 04/24 AO
DuréeAuto.2 mois3 mois6 mois9 mois1 an2 ans5 ans10 ansMax.
PeriodDayWeek
More graphics
AB Science specializes in the research, development and marketing of protein kinase inhibitors (PIKs), therapeutic molecules used in the treatment of cancerous tumours, inflammatory and neurodegenerative diseases in both human and health animal.
More information about the company
ABOUT
© 2023 Outperformance. All rights reserved.
Quotes are provided by Factset, Morningstar and S&P Capital IQ
1693596400
#Science #biggest #fall #SRD #market #close #Friday #September #Today #p.m